Merck & Co., Inc. (MRK)
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry. Just last month, AWS and General Catalyst announced their partnership to speed up the development and deployment of healthcare AI tools.
Jim Cramer Says These 2 Large Cap Dividend Stocks Are Hot February Buys
Media personality Jim Cramer often makes bold statements about companies and a lot of times, he proves himself correct.
Merck: 4 No-Brainer Reasons to Buy This Dip
Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the market can be unforgiving when companies even slightly miss expectations or forecasts.
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What's Next?
Merck & Co . (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows on popular television channels we're all exposed to.
Merck: Don't Fight The Tape, How Low Can It Go?
Despite Merck & Co., Inc.'s strong fundamentals and promising pipeline, current negative sentiment suggests avoiding the stock until it stabilizes and shows signs of recovery. Merck's stock is undervalued but could face further declines, with potential prices dropping to $80, $70, or even $60. The stock market's irrationality can outlast your solvency; avoid the pain of catching a falling knife by waiting for a confirmed bottom in MRK stock.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Should You Pick MRK Stock At $90?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, compared to the consensus estimates of $15.5 billion and $1.62, respectively.
Guggenheim Securities' Vamil Divan breaks down Merck's stock drop
Vamil Divan, Guggenheim Securities biopharmaceutical analyst, joins 'Power Lunch' to discuss Merck's troubles in China.
Merck: Ideal Case Of Why I Love Option Collars (Upgrade To Buy)
Merck's current high-risk profile led me to initially rate it a strong sell, but recent technical indicators suggested a potential bottom near $100. I've upgraded MRK to a buy, using a "Dog Collar" strategy: buying a put option and selling a call option to limit risk. This approach offers controlled outcomes, with $18 upside and $7 downside risk, ensuring I manage risk while seeking potential gains.
Why Merck Stock Is Plummeting Today
Shares of Merck (MRK -9.66%) were trading lower on Tuesday. The company's stock had lost 10.1% as of 2 p.m.
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Healthcare costs are rising, with PwC projecting the highest commercial healthcare spending growth in 13 years, impacting consumers and insurance companies negatively. Healthcare stocks, including Merck & Co., Inc., have underperformed the S&P 500, making them attractive as the broader market reaches high valuations. Despite Merck's recent 30% stock decline due to poor guidance and Gardasil challenges, I believe it offers good long-term value.
Merck & Co., Inc. (MRK) Q4 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q4 2024 Results Conference Call February 4, 2025 9:00 AM ET Company Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dr. Dean Li - President of Merck Research Labs Conference Call Participants Umer Raffat - Evercore ISI Terence Flynn - Morgan Stanley Luisa Hector - Berenberg Mohit Bansal - Wells Fargo Daina Graybosch - Leerink Partners Geoff Meacham - Citi Chris Schott - JPMorgan Tim Anderson - Bank of America Akash Tewari - Jefferies Trung Huynh - UBS Vamil Divan - Guggenheim Courtney Breen - Bernstein James Shin - Deutsche Bank Operator Thank you for standing by. Welcome to the Merck & Company Q4 Sales and Earnings Conference Call.
